subject area of
- Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration Journal Articles
- Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration Journal Articles
- Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis Journal Articles
- Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response Journal Articles
- Genetic Risk Factors Are Not Associated with Wet Age-Related Macular Degeneration Treatment Response to Ranibizumab Journal Articles
- IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Journal Articles
- Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration Journal Articles
- MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY Journal Articles
- Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study) Journal Articles
- PIGMENT EPITHELIAL DETACHMENT THICKNESS AND VARIABILITY AFFECTS VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Journal Articles
- Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation Journal Articles
- Ranibizumab and the eye Journal Articles
- Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing Journal Articles
- SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY Journal Articles
- Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next? Journal Articles